Relevant bibliographies by topics / Antineoplastic agents: pharmacology. Cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Antineoplastic agents: pharmacology. Cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antineoplastic agents: pharmacology. Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antineoplastic agents: pharmacology. Cancer"

1

Lichtman, Stuart M., J. Andrew Skirvin, and Sunitha Vemulapalli. "Pharmacology of antineoplastic agents in older cancer patients." Critical Reviews in Oncology/Hematology 46, no. 2 (2003): 101–14. http://dx.doi.org/10.1016/s1040-8428(02)00120-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Melamed, Andra J., and Michael L. Kleinberg. "Handling Considerations for Cancer Chemotherapeutic Agents." Drug Intelligence & Clinical Pharmacy 22, no. 3 (1988): 247–51. http://dx.doi.org/10.1177/106002808802200317.

Full text
Abstract:
Since the introduction of antineoplastic agents in the 1940s, there have been reports of the effects of these agents on workers who have had prolonged contact with them. The Regional Oncology Drug Information Center (RODIC) at Memorial Sloan-Kettering Cancer Center receives numerous inquiries nationwide regarding our policies and procedures for handling antineoplastic agents. In August 1987, RODIC conducted a computerized literature search on the handling of antineoplastic agents and the risks to hospital employees coming in contact with these agents. We used the MEDLINE system from 1966 to th
APA, Harvard, Vancouver, ISO, and other styles
3

Garcia, Gwenalyn, and Jean Paul Atallah. "Antineoplastic agents and thrombotic microangiopathy." Journal of Oncology Pharmacy Practice 23, no. 2 (2016): 135–42. http://dx.doi.org/10.1177/1078155216628324.

Full text
Abstract:
Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text
Abstract:
Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information
APA, Harvard, Vancouver, ISO, and other styles
5

Barreto, Jason N., Kristen B. McCullough, Lauren L. Ice, and Judith A. Smith. "Antineoplastic Agents and the Associated Myelosuppressive Effects." Journal of Pharmacy Practice 27, no. 5 (2014): 440–46. http://dx.doi.org/10.1177/0897190014546108.

Full text
Abstract:
Bone marrow is a complex organ responsible for the regulation of hematopoietic cell distribution throughout the human body. Patients receiving antineoplastic agents as a therapeutic intervention for hematologic malignancy often experience varying degrees of myelotoxicity. Antineoplastic agents cause hypocellularity in marrow resulting in a reduction in hematopoietic tissue activity and a corresponding decline in cell production. Quantifying the adverse effects on hematopoiesis is based on the properties of a single agent, the use of individual drugs within a combination chemotherapy regimen, a
APA, Harvard, Vancouver, ISO, and other styles
6

Adams, Val R. "Evolving role of antineoplastic agents in colorectal cancer." American Journal of Health-System Pharmacy 63, no. 9_Supplement_2 (2006): S4—S11. http://dx.doi.org/10.2146/ajhp060112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Syrigou, Ekaterini, Nektaria Makrilia, Ioanna Koti, Muhammad W. Saif, and Kostas N. Syrigos. "Hypersensitivity reactions to antineoplastic agents: an overview." Anti-Cancer Drugs 20, no. 1 (2009): 1–6. http://dx.doi.org/10.1097/cad.0b013e32831961b3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Waddell, J. Aubrey, and Dominic A. Solimando. "Irinotecan and Carboplatin (IC) Regimen for Lung Cancer." Hospital Pharmacy 44, no. 9 (2009): 740–45. http://dx.doi.org/10.1310/hpj4409-740.

Full text
Abstract:
The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Lee, Jessica N., J. Aubrey Waddell, and A. Solimando Dominic. "Gemcitabine and Erlotinib (GE) Regimen for Pancreatic Cancer." Hospital Pharmacy 47, no. 1 (2012): 19–23. http://dx.doi.org/10.1310/hpj4701-19.

Full text
Abstract:
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
APA, Harvard, Vancouver, ISO, and other styles
10

Yang, Jessie, Dominic A. Solimando, and J. Aubrey Waddell. "Docetaxel and Cisplatin Regimen for Non-Small-Cell Lung Cancer." Hospital Pharmacy 48, no. 7 (2013): 550–57. http://dx.doi.org/10.1310/hpj4807-550.

Full text
Abstract:
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antineoplastic agents: pharmacology. Cancer"

1

Martinsson, Petra 1974. "Pharmacological studies of CHS 828 and etoposide induced tumour cell death /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2001. http://publications.uu.se/theses/91-554-5157-8/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yang, Xiaotong, and 楊曉彤. "The anticancer mechanisms of polysaccharide peptide (PSP) derived fromthe Chinese medicinal fungus coriolus versicolor." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31246229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Alina. "New polyamine analogues as potential antineoplastic agents." Scholarly Commons, 2000. https://scholarlycommons.pacific.edu/uop_etds/2680.

Full text
Abstract:
The naturally occurring polyamines play an essential role in cell growth and proliferation. The levels of polyamines have been shown to increase in rapidly proliferating cancer cells. Therefore, compounds that inhibit enzymes in polyamine biosynthetic pathway may have therapeutic potential. Compounds capable of providing both in vitro and in vivo inhibition of almost all enzymes in the polyamine biosynthetic pathway are known. An exception is the lack of an agent that inhibits spermidine/spermine N 1 -acetyltransferase (SSAT), the rate-limiting enzyme in the catabolism of polyamines. The desig
APA, Harvard, Vancouver, ISO, and other styles
4

Nylén, Urban D. "Interactive antiproliferative mechanisms when 5-fluorouracil is combined with cisplatin or ionizing radiation : an in vivo and in vitro experimental study /." Stockholm, 2000. http://diss.kib.ki.se./2000/91-628-4480-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Parker-, Johnson Kitani A. "An evaluation of novel antineoplastic agent on prostate cancer." DigitalCommons@Robert W. Woodruff Library, Atlanta University Center, 2003. http://digitalcommons.auctr.edu/dissertations/3074.

Full text
Abstract:
This study examines the effects of novel antineoplastic agents(isochalcones) on human metastatic prostate cancer cell lines by screening cells for their relative antiproliferative effects, measuring the protein expression levels of specific oncogenes by Western blotting, and evaluating an array of genes ( 5184) to determine possible mechanisms of action of these novel isochalcones. The array data were supported by real-time polymerase chain reaction (PCR) techniques. The antineoplastic agents were screened in human metastatic prostate cancer cell lines (LNCaP, DU145, PC-3, and MDA-PCa-2b) and
APA, Harvard, Vancouver, ISO, and other styles
6

Zhu, Yanting. "Exploring alternative cytotoxic strategies for cancer treatment." HKBU Institutional Repository, 2014. https://repository.hkbu.edu.hk/etd_oa/65.

Full text
Abstract:
Triggering direct cytotoxicity has been the most common strategy for developing cancer treatments. The cytotoxic regimens currently used in the clinic mainly include radiation therapy, classic chemotherapeutic drugs (e.g. DNA damaging drugs and anti-mitotic drugs) and selected new targeted drugs. Although these therapies are the standard of care for most cancer patients, they suffer significant limitations: responses to these therapies vary significantly between cancer types and patients; sensitive cancers tend to acquire resistance; and they cause serious toxicity, particularly to dividing ce
APA, Harvard, Vancouver, ISO, and other styles
7

Arthasery, Phyllis Pinney Kevin G. "Discovery and development of unique small molecule chromene based ligands and combretastatin analogs as potential second generation vascular disrupting agents towards cancer chemotherapy." Waco, Tex. : Baylor University, 2005. http://hdl.handle.net/2104/3020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

陳志強. "中醫藥抗腫瘤復發轉移文獻研究". HKBU Institutional Repository, 2012. http://repository.hkbu.edu.hk/etd_ra/1336.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Allan, Lucy Jane. "Development and pharmacology of mitomycin C albumin microspheres." Thesis, University of Strathclyde, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.319281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Williams, Elizabeth G. L. "Total synthesis of novel analogues and hybrids of the anti-cancer agents dictyostatin and discodermolide." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610776.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antineoplastic agents: pharmacology. Cancer"

1

Ramaswamy, Govindan, ed. Essential cancer pharmacology: The prescriber's guide. Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Swanson, Hollie. Flavonoids, inflammation and cancer. World Scientific, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hellmann, K., and Walter Rhomberg. Razoxane and dexrazoxane: Two multifunctional agents : experimental and clinical results. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Frederick, Valeriote, Corbett Thomas H, and Baker Laurence H, eds. Cytotoxic anticancer drugs: Models and concepts for drug discovery and development : proceedings of the Twenty-Second Annual Cancer Symposium, Detroit, Michigan, USA, April 26-28, 1990. Kluwer Academic, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kong, Ah-Ng Tony. Inflammation, oxidative stress, and cancer: Dietary approaches for cancer prevention. Taylor & Francis, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

J, Houghton Peter, and Houghton Janet A, eds. Preclinical and clinical modulation of anticancer drugs. CRC Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Siddik, Zahid H. Checkpoint controls and targets in cancer therapy. Humana Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

P, Hacker Miles, Lazo John S, and Tritton Thomas R, eds. Organ directed toxicities of anticancer drugs: Proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs, Burlington, Vermont, USA, June 4-6, 1987. Nijhoff, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Checkpoint controls and targets in cancer therapy. Humana Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Free radicals effect on cytostatica, vitamins, hormones and phytocompounds with respect to cancer. Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antineoplastic agents: pharmacology. Cancer"

1

Schmähl, D., M. R. Berger, B. K. Keppler, and T. Klenner. "New Antineoplastic Agents." In Cancer Therapy. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74683-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bloch, Alexander. "Antineoplastic Agents and Cancer Cell Differentiation." In Cancer Biology and Therapeutics. Springer US, 1987. http://dx.doi.org/10.1007/978-1-4757-9564-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Balis, Frank M. "The pharmacology of antineoplastic agents in children." In The Role of Pharmacology in Pediatric Oncology. Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-4267-7_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ehrke, M. Jane, and Enrico Mihich. "Immunoregulation by Cancer Chemotherapeutic Agents." In Pharmacology. Springer US, 1985. http://dx.doi.org/10.1007/978-1-4615-9406-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Grant, Stefan C., and Mark G. Kris. "New antineoplastic agents in lung cancer 1988–1993." In Cancer Treatment and Research. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2630-8_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

van Groeningen, C. J. "Technical Developments in the Delivery of Antineoplastic Agents." In Progress in Regional Cancer Therapy. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74818-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kunder, Sushil Kiran, and Avinash Arivazhahan. "Hormonal Agents in the Pharmacotherapy of Cancer." In Introduction to Basics of Pharmacology and Toxicology. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6009-9_65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jarman, Michael. "Design of Novel Anti-Endocrine Agents." In New Approaches in Cancer Pharmacology: Drug Design and Development. Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77874-2_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhang, Lan, Yaxin Zheng, Mao Tian, Shouyue Zhang, Bo Liu, and Jinhui Wang. "Targeting Cancer Cell Death with Small Molecule Agents for Potential Therapeutics." In Methods in Pharmacology and Toxicology. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3588-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stewart, D. J. "Human Central Nervous System Pharmacology of Antineoplastic Agents: Implications for the Treatment of Brain Tumors." In Brain Oncology Biology, diagnosis and therapy. Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_71.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antineoplastic agents: pharmacology. Cancer"

1

Bradley, Cathy J., and Marcelo Coca Perraillon. "Abstract PR10: Fewer rural cancer patients treated with antineoplastic agents." In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-pr10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antineoplastic agents: pharmacology. Cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography